Ysabella Z A Van Sebille

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5173583/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Digital education strategies around the world: practices and policies. Irish Educational Studies, 2022, 41, 85-106.	2.5	15
2	Oral-Gut Microbiome Axis in the Pathogenesis of Cancer Treatment-Induced Oral Mucositis. Frontiers in Oral Health, 2022, 3, 881949.	3.0	17
3	Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. Gut Microbes, 2021, 13, 1979878.	9.8	38
4	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2020, 126, 4423-4431.	4.1	540
5	Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. Integrative Cancer Therapies, 2020, 19, 153473542092849.	2.0	35
6	Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. Supportive Care in Cancer, 2020, 28, 5059-5073.	2.2	40
7	Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Supportive Care in Cancer, 2019, 27, 4011-4022.	2.2	51
8	Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity. Experimental Biology and Medicine, 2019, 244, 1178-1185.	2.4	10
9	Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis. Expert Review of Gastroenterology and Hepatology, 2019, 13, 485-496.	3.0	51
10	Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis. Current Opinion in Supportive and Palliative Care, 2018, 12, 187-197.	1.3	43
11	Dacomitinibâ€induced diarrhea: Targeting chloride secretion with crofelemer. International Journal of Cancer, 2018, 142, 369-380.	5.1	18
12	Selective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat Model. Chemotherapy, 2018, 63, 284-292.	1.6	5
13	Routine assessment of the gut microbiome to promote preclinical research reproducibility and transparency. Gut, 2017, 66, 1869-1871.	12.1	3
14	Dacomitinibâ€induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. International Journal of Cancer, 2017, 140, 2820-2829.	5.1	27
15	Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemotherapy and Pharmacology, 2017, 79, 431-434.	2.3	10
16	Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Supportive and Palliative Care, 2016, 10, 152-156.	1.3	6
17	Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer. Supportive Care in Cancer, 2016, 24, 1779-1788.	2.2	16
18	Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. Molecular Cancer Therapeutics, 2016, 15, 1376-1386.	4.1	114

#	Article	IF	CITATIONS
19	A novel <i>in vitro</i> platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. Experimental Biology and Medicine, 2016, 241, 1386-1394.	2.4	8
20	TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea. Molecular Cancer Therapeutics, 2016, 15, 2767-2779.	4.1	38
21	Cytokineâ€mediated blood brain barrier disruption as a conduit for cancer/chemotherapyâ€associated neurotoxicity and cognitive dysfunction. International Journal of Cancer, 2016, 139, 2635-2645.	5.1	108
22	Editorial Comment. Current Opinion in Supportive and Palliative Care, 2015, 9, 155-156.	1.3	1
23	Toll-like receptor 4 signaling: A common biological mechanism of regimen-related toxicities. Cancer Treatment Reviews, 2015, 41, 122-128.	7.7	34
24	Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics. Current Oncology Reports, 2015, 17, 50.	4.0	59
25	ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis. Cancer Treatment Reviews, 2015, 41, 646-652.	7.7	53